p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer

Park, Eunhyang; Han, Hyunho; Choi, Seong–Jun; Park, Hyunjin; Woo, Ha-Young; Jang, Mi; Shim, Hyo Sup; Hwang, Sohyun; Kang, Haeyoun; Cho, Nam Hoon

doi:10.3390/diagnostics12030579

Cited by 18 publications

(17 citation statements)

References 30 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 60 , 61 However, several recent studies have reported a high frequency of p53 overexpression in tumors with TP53 nonsense mutations in the carboxyl terminus, as in the two cases in this study. 62 , 63 , 64 Although the mechanism of p53 overexpression in these cases has not been fully elucidated, it is possible that these mutations were not subject to nonsense‐medicated decay. 62 Moreover, the p53 oligomerization domain (amino acids: 325‐356) nonsense mutants could have received transcriptional feedback regulation.…”

Section: Discussionmentioning

confidence: 99%

Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma

et al. 2023

View full text Add to dashboard Cite

Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT‐SCC) vary from case to case, the spatial spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT‐SCCs, we performed whole‐exome sequencing by collecting 16 samples from histologically different parts of two MCT‐SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing SCC and case 2: nonkeratinizing SCC and anaplastic carcinoma) and had different somatic mutation profiles by histological findings. Mutation signature analysis revealed a significantly enriched apolipoprotein B mRNA editing enzyme catalytic subunit (APOBEC) signature at all sites. Intriguingly, the spread of genomic alterations within the tumor and the clonal evolution patterns from nonmalignant epithelium to cancer sites differed between cases. TP53 mutation and copy number alterations were widespread at all sites, including the nonmalignant epithelium, in case 1. Keratinizing and nonkeratinizing SCCs were differentiated by the occurrence of unique somatic mutations from a common ancestral clone. In contrast, the nonmalignant epithelium showed almost no somatic mutations in case 2. TP53 mutation and the copy number alteration similarities were observed only in nonkeratinizing SCC samples. Nonkeratinizing SCC and anaplastic carcinoma shared almost no somatic mutations, suggesting that each locally and independently arose in the MCT. We demonstrated that two MCT‐SCCs with different histologic findings were highly heterogeneous tumors with clearly different clones associated with APOBEC‐mediated mutagenesis, suggesting the importance of evaluating intratumor histological and genetic heterogeneity among multiple sites of MCT‐SCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Still, there is a lack of clinical, pathological, and epidemiological data on breast cancer subtypes and P53 immunoexpression [ 9 ]. P53 gene mutations are believed to be associated with 70% to 80% of triple-negative breast cancer cases (TNBC) [ 11 ]. In turn, triple-negative breast cancer represents about 12% to 20% of the breast cancer subtypes.…”

Section: Discussionmentioning

confidence: 99%

Patterns of Immunohistochemical Expression of P53, BCL2, PTEN, and HER2/neu Tumor Markers in Specific Breast Cancer Lesions

Bealy

Abugooda

Ahmed

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. This study aimed to associate the expression of P53, BCL2, PTEN, and HER2/neu tumor markers in specific breast cancer lesions. Methods. This study analyzed the immunohistochemical expression of P53, BCL2, PTEN, and HER2/neu tumor markers for 306 patients who presented with lesions. Tissue blocks and patients’ identification data were retrieved from the department of pathology, AL Madinah Almonwarah hospital, Al Madinah, UAE. Results. Of the 306 patients, 104 had benign lesions and 202 had malignancy (including 194 females and 6 males). Most females were presented with invasive ductal carcinoma (IDC), followed by infiltrating ductal carcinoma, and invasive lobular carcinoma (ILC), representing 70%, 23.2%, and 3.7%, respectively. Positive P53, BCL2, PTEN, and HER2 were identified in 20.8%, 11.9%, 91%, and 18.3%, respectively. Conclusion: The expression of P53, BCL2, PTEN, and HER2/neu tumor markers among Saudi patients with breast cancer is relatively similar in many parts of the world.

show abstract

“…2,14 Additionally, all three tumors showed aberrant expression of p53 IHC, which correlates with TP53 mutation. 17 Since conventional YSTs do not harbor TP53 mutation, 18 p53 IHC may be a helpful tool to differentiate somatically derived YST and conventional YST. 19 Previously, the frequency of YST-like differentiation in ovarian carcinomas had not been reported.…”

Section: Discussionmentioning

confidence: 99%

Ovarian Mucinous Carcinoma with a Yolk sac Tumor-Like Component: A Report of Three Cases with a Literature Review for Prognostic Analysis

et al. 2022

View full text Add to dashboard Cite

The most common subtype of ovarian carcinoma associated with somatically derived yolk sac tumor (YST) is endometrioid carcinoma. Only two cases of ovarian mucinous carcinomas associated with YST have been reported; herein, we present three additional patients, along with a review of previous literature and our pathology archives to analyze the tumor prognosis. The patients’ ages ranged from 38 to 53 years. Two patients had FIGO stage 1 tumors, and one patient had a stage 3 tumor. Two patients died of the disease within a year, and one patient survived with distant metastasis (32 months after surgery). In all three tumors, the YST-like component comprised less than 5% of the total tumor area. Together with the two previously reported mucinous carcinomas with a YST-like component, the prognosis of the five mucinous carcinomas with a YST-like component were compared with that of 19 conventional mucinous carcinomas resected at our hospital. The survival curves were estimated using the Kaplan–Meier method. As a result, the overall survival rate of patients with mucinous carcinomas with a YST-like component was significantly lower than that of patients with conventional mucinous carcinomas ( P = .0014). Our study indicates that the presence of a YST-like component in mucinous carcinomas would be a strong prognostic indicator.

show abstract

p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer

Cited by 18 publications

References 30 publications

Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma

Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma

Patterns of Immunohistochemical Expression of P53, BCL2, PTEN, and HER2/neu Tumor Markers in Specific Breast Cancer Lesions

Ovarian Mucinous Carcinoma with a Yolk sac Tumor-Like Component: A Report of Three Cases with a Literature Review for Prognostic Analysis

Contact Info

Product

Resources

About